English
Le forbairt go mear ar an tionscal bithchógaisíochta, tá úsáid na teicneolaíochta cultúir cille chun taighde a dhéanamh ar vacsaíní, antasubstaintí monachlónacha agus drugaí eile tar éis éirí mar threocht. Is earraí inchaite iad Cellfactory víreas zoster. Is iad na hairíonna cliniciúla fiabhras, go príomha macúil, papules, vesicles agus galar scrathach i mbaisceanna, agus fiú bás i gcásanna tromchúiseacha. Is í an vacsaín deilgneach an bealach is sábháilte agus is éifeachtaí chun deilgneach a chosc. Glacann an vacsaín varicella brú maolaithe den víreas varicella OKa, a úsáidtear go coitianta ar fud an domhain, agus tá sé déanta ag cultúr cealla diploid daonna MRC-5. Is comhlacht scaoilte bán bó Finne é cuma an táirge reoite-triomaithe, agus is leacht buí pale é tar éis a dhíscaoileadh. Ní hamháin go gcosnaíonn an vacsaín deilgneach i gcoinne deilgneach, ach cuireann sé cosc ar aimhréití ó shingles deilgneach. a úsáidtear go coitianta i gcultúr na gceall ar scála mór, a bhfuil ról tábhachtach acu i dtáirgeadh mórscála vacsaíní varicella.
Ó 1 Lúnasa, 2018, tá an vacsaín varicella san áireamh i bPlean Imdhíonta Bardasach Shanghai, agus tá aird na ndaoine ar an vacsaín varicella ag leanúint ar aghaidh. méadú, agus tá méid mór margaidh aige. Tá sé cruthaithe freisin ag eispéiris phraiticiúla éagsúla, i gcomparáid le hábhair inchaite cultúir eile, go bhfuil buntáistí ag baint le húsáid monarchana cille chun vacsaín varicella a tháirgeadh ar scála mór, go bhfuil níos lú truaillithe, táirgeacht ard, éagsúlacht bheag bhaisc go bhaisc, agus am oibríochta gearr. . Modh cultúr cille tábhachtach d'fhiontair.
Ina theannta sin, is féidir an mhonarcha cille a úsáid freisin le haghaidh táirgeadh ar scála mór vacsaín MMR, vacsaín heipitíteas A, vacsaín polaimiailítis, etc. Le forbairt go mear na teicneolaíochta bithleighis, tá raon feidhme an iarratais den inchaite seo beidh sé níos leithne agus níos leithne freisin.
In addition, the cell factory can also be used for large-scale production of MMR vaccine, hepatitis A vaccine, polio vaccine, etc. With the rapid development of biomedical technology, the application scope of this consumable will also become wider and wider.
The FAI climbed 5.9 percent year-on-year in the first 11 months of 2018, quickening from the 5.7-percent growth in Jan-Oct, the National Bureau of Statistics (NBS) said Friday in an online statement.
The key indicator of investment, dubbed a major growth driver, hit the bottom in August and has since started to rebound steadily.
In the face of emerging economic challenges home and abroad, China has stepped up efforts to stabilize investment, in particular rolling out measures to motivate private investors and channel funds into infrastructure.
Friday's data showed private investment, accounting for more than 60 percent of the total FAI, expanded by a brisk 8.7 percent.
NBS spokesperson Mao Shengyong said funds into weak economic links registered rapid increases as investment in environmental protection and agriculture jumped 42 percent and 12.5 percent respectively, much faster than the average.
In breakdown, investment in high-tech and equipment manufacturing remained vigorous with 16.1-percent and 11.6-percent increases respectively in the first 11 months. Infrastructure investment gained 3.7 percent, staying flat. Investment in property development rose 9.7 percent, also unchanged.